TCWP’s NovoCure NVCR Stock Holding History

TCWP’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-147	Closed	-$12K	–	1236
2022 Q1	$12K	Buy	+147	New	+$10.8K	﹤0.01%	839

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TCWP's NVCR Position: Q2 2022 in Review

TCWP sold out of NovoCure (NVCR) in Q2 2022, closing a stake of 147 shares — an estimated $12K sold.

TCWP first reported a position in NVCR in Q1 2022 and held it in 1 quarter. The position peaked at $12K in Q1 2022. 316 funds tracked by Wall St. Rank hold NVCR as of Q2 2022.

TCWP reported no remaining NovoCure position as of Q2 2022 after selling out during the quarter.
TCWP sold 147 NovoCure shares in Q2 2022, an estimated $12K.
TCWP first reported a position in NovoCure in Q1 2022 and held it in 1 quarter.
TCWP's NovoCure position peaked at $12K in Q1 2022.
316 funds tracked by Wall St. Rank held NovoCure as of Q2 2022.

Based on TCWP's 13F filing for Q2 2022, filed 15 Aug 2022.